In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.
AUTOR(ES)
Otto, M J
RESUMO
WIN 51711 (5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methylisoxazole), a new antipicornavirus drug, is a potent inhibitor of human entero- and rhinoviruses at concentrations not inhibitory to HeLa cell growth. In plaque reduction assays, WIN 51711 reduced plaque formation by 9 enteroviruses and 33 rhinoviruses, with MICs of 0.004 to 0.17 and 0.004 to 6.2 micrograms/ml, respectively. Addition of WIN 51711 to infected cells at concentrations of 0.02 to 5.0 micrograms/ml reduced the yield of picornaviruses by 90%. Other RNA viruses (nonpicornaviruses) and DNA viruses were unaffected by the compound.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=180179Documentos Relacionados
- In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.
- Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.
- In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.
- Broad-Spectrum Antimicrobial Activity of a New Triazenoimidazole
- In vitro antibacterial activity of faeriefungin, a new broad-spectrum polyene macrolide antibiotic.
